Abstract Lines

Our Pipeline

Targeting fundemental biology for radical therapeutic benifits

Abstract Lines

Indication

Discovery

Preclinical

Phase I

Phase II

CB-18

Peptide mitophagy

activator

CB-1902

Small molecule

mitophagy activator

Penetrating Keratoplasty
Macular degeneration
Muscular 
Dystrophy
Neuro-
Degeneration

CB-1025

Acidifying

nanoparticles

Liver
Disease
Lysosomal
Diseases
Abstract Futuristic Background

We Integrate With Your Ecosystem

I'm a paragraph. Click here to add your own text and edit me. It’s easy. Just click “Edit Text” or double click me to add your own content and make changes to the font. I’m a great place for you to tell a story and let your users know a little more about you.